The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Gwen Nichols, MD, chief medical officer of Blood Cancer United, discusses generational financial toxicity in oncology, particularly in pediatric acute leukemia care, and
Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai,
Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, discusses the biggest highlights from
The first issue of 2026 features an article exploring the dual journey of a myeloma patient’s treatment alongside the early development of cilta-cel,
In this video, the group discusses unmet needs in large cell lymphoma and novel agents, including the CELLMod golcadomide.
In patients with polycythemia vera receiving standard of care therapy, treatment with rusfertide continued to yield a statistically significant reduction in the mean
Epcoritamab in combination with rituximab and lenalidomide has the potential to be the new standard of care in patients with second-line follicular lymphoma,
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with significantly higher rates of severe toxicity following B-cell maturation antigen (BCMA)-targeted CAR T-cell
In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at
SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical
